Frontotemporal dementia (FTD) is a clinical syndrome that presents as a gradual decline in behavior caused by neurodegeneration. FTD the leading cause of dementia in people under 60 and the second most common type of dementia in all ages. The most common pathology in FTD are inclusion of transactive response DNA binding protein 43kDa (TDP-43). A biomarker for specific for TDP-43 pathology is desperately needed to assist with early and accurate diagnosis and improve are for individuals with FTD.
My research aims to develop a mass spectrometry assay to assist with diagnosis specific for FTD with TDP-43 inclusions.
For an up-to-date list of my publications, see Google Scholar.
Year 2022
Type Trainee Award
Partner(s) 
CLEAR Foundation